Iconovo establishes Iconovo Pharma AB as a subsidiary for pharmaceutical sales in the Nordic countries
Iconovo AB (publ), that develops complete inhalation products for a global market, has registered the subsidiary Iconovo Pharma AB with the Swedish Companies Registration Office. This is part of the previously communicated strategy to establish an infrastructure for in-house pharmaceutical sales in the Nordic market. Iconovo's goal is to reach sales revenues of SEK 200 million by 2026, of which approximately one third is estimated to come from Iconovo Pharma.
Iconovo and TOA sign agreement for development of a generic product
Iconovo AB (publ), that develops complete inhalation products for a global market, and TOA Pharmaceutical Co., Ltd, which develops generic products for the Japanese market announced today that they have signed a feasibility agreement to use an inhaler from Iconovo for a generic product development. The feasibility agreement has a value of EUR 202.000 to be paid over the coming 12 months.
Nomination Committee appointed at Iconovo
At the Annual General Meeting of 8 May 2020, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year.
First granted ICOone® patent in China
The Chinese Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone.
Abbreviated interim report 1 January – 30 September 2021
New nasal inhaler has great potential in treatment of COVID-19
Iconovo meets US Quality System regulation for medical devices
Iconovo AB (publ), that develops complete inhalation products for a global market today announces that the company’s Quality Management System (QMS) has been upgraded to meet the US Quality System Regulation (QSR 21 CFR 820) for medical devices. The company’s development and documentation process must comply with this FDA regulation to enable registration and marketing of medical device products in the US.
Second ICOres® patent granted in Japan
Japan Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device, ICOres. Iconovo has previously granted ICOres patents in Japan, USA, Sweden, Europe (EPO) and China. The new patent covers the technology used in many of Iconovo’s projects like generic Symbicort©.
Abbreviated interim report 1 January – 30 June 2021
Expanded agreement doubles royalty potentialKey figures in TSEK unless otherwise indicated Apr-Jun 2021Apr-Jun 2020Jan-Jun 2021Jan-Jun 2020Jan-Dec 2020Net…
Iconovo receives an order for additional work from ISR for development of a nasal COVID-19 vaccine
Iconovo AB (publ), a company developing complete inhalation products for a global market, today announced that it has received an order from the immunotherapy company ISR Immune System Regulation AB (ISR), a subsidiary of ISR Immune System Regulation Holding AB (publ), for additional work for the ongoing project with inhaled COVID-19 vaccine with a development of a nasal version of Iconovo's inhaler ICOone. The additional order may give Iconovo up to 4.9 MSEK in addition to previously announced agreement.
Iconovo AB has completed a directed share issue of SEK 75 million
The Board of Directors of Iconovo AB (publ) (”Iconovo” or the ”Company”) has, pursuant to the authorisation granted by the Annual General Meeting of the Company that was held on 19 May 2021, resolved on a directed share issue of 1,071,500 new shares, corresponding to approximately 13.8 per cent of the total number of shares outstanding, at a subscription price of SEK 70 per share (the “Issue”). This means that the Company receives SEK 75,005,000 before transaction costs. The subscription price in the Issue has been determined through an accelerated bookbuilding procedure (the ”Bookbuilding”). The Issue was subscribed for by several new Swedish and international institutional investors, such as Alcur Fonder, FE Fonder and Humle Fonder, as well as several existing owners, such as Andra AP-fonden, Fjärde AP-fonden, Handelsbanken Fonder and Länsförsäkringar Fondförvaltning AB.
